Item 1.01 Entry Into a Material Definitive Agreement
On January 11, 2021, Enveric Biosciences, Inc. (the "Company") entered into a
Securities Purchase Agreement (the "Purchase Agreement") with certain
institutional and accredited investors (the "Purchasers"), pursuant to which the
Company agreed to issue and sell in a registered direct offering (the
"Offering") an aggregate of 2,221,334 shares (the "Shares") of common stock of
the Company, par value $0.01 per share, at an offering price of $4.5018 per
share, for gross proceeds of approximately $10,000,000 before the deduction of
fees and offering expenses. In addition, under the Purchase Agreement, the
Purchasers may choose to purchase pre-funded warrants (the "Pre-funded
Warrants") in lieu of shares of Common Stock.
As of January 11, 2021, the Company had outstanding shares of common stock
(without giving effect to the issuance and sale of the Shares pursuant to the
Purchase Agreement) of 11,595,109.
The Pre-funded Warrants have an exercise price of $0.01 per share. The
Pre-funded Warrants are immediately exercisable and may be exercised at any time
after their original issuance until such Pre-funded Warrants are exercised in
full. A holder of a Pre-funded Warrant may not exercise any portion of such
holder's Pre-funded Warrants to the extent that the holder, together with its
affiliates, would beneficially own more than 4.99% (or, at the election of the
holder, 9.99%) of the Company's outstanding shares of Common Stock immediately
after exercise (the "Beneficial Ownership Limitation"), except that upon at
least 61 days' prior notice from the holder to the Company, the holder may
increase the beneficial ownership limitation to up to 9.99% of the number of
shares of Common Stock outstanding immediately after giving effect to the
exercise.
The Shares, the Pre-funded Warrants, and the shares of Common Stock issuable
upon the exercise of the Pre-funded Warrants (the "Pre-funded Warrant Shares")
are being offered by the Company pursuant to a shelf registration statement on
Form S-3 (File No. 333-233260) (the "Shelf Registration Statement"), previously
filed with the Securities and Exchange Commission (the "SEC") on August 14,
2019, and declared effective by the SEC on November 19, 2019.
Pursuant to the Purchase Agreement, in a concurrent private placement (the
"Private Placement"), the Company agreed to issue to the Purchasers,
unregistered warrants to purchase up to 1,666,019 shares of Common Stock (the
"Warrants"). The Warrants are exercisable immediately upon issuance and
terminate five years following issuance and are exercisable at an exercise price
of $4.9519 per share, subject to adjustment as set forth therein. A holder of
Warrants will not have the right to exercise any portion of its Warrants if the
holder, together with its affiliates, would beneficially own in excess of the
Beneficial Ownership Limitation; provided, however, that upon 61 days' prior
notice to the Company, the holder may increase or decrease the Beneficial
Ownership Limitation, provided that in no event shall the Beneficial Ownership
Limitation exceed 9.99%.
The Warrants and the shares of our Common Stock issuable upon the exercise of
the Warrants (the "Warrant Shares") are not being registered under the
Securities Act of 1933, as amended (the "Securities Act"), are not being offered
pursuant to the Shelf Registration Statement, and are being offered pursuant to
the exemption provided in Section 4(a)(2) under the Securities Act and Rule
506(b) promulgated thereunder.
To induce the Purchasers into the Purchase Agreement, the Company also entered
into a registration rights agreement, dated January 11, 2021 (the "Registration
Statement"), with the Purchasers, pursuant to which, among other things, the
Company has agreed to prepare and file with the Securities and Exchange
Commission a registration statement to register for resale of all of the Warrant
Shares.
In addition, the Company entered into a letter agreement (the "Letter
Agreement") with Alpha Capital Anstalt ("Alpha"). Under the Letter Agreement,
(i) the Company agreed to register 1,791,923 shares of Common Stock (the "Series
B Warrant Shares") issuable upon the exercise of certain Series B Warrants
issued to Alpha on December 31, 2020, which have an exercise price of $0.01 per
share, (ii) the Series B Warrant Shares will not be subject to an existing
lock-up agreement between the Company and Alpha and Alpha will no longer be
subject to any limitations on its ability to dispose of the Series B Warrant
Shares that are imposed by the Company to the extent permitted by applicable
rules and regulations, (iii) Alpha agreed to limit its sales of Common Stock on
each trading day to no more than 10% of the daily reported trading volume of
Common Stock on the Nasdaq Stock Market for such trading day, provided, such
limitation shall terminate if the closing price of the Company's shares of
common stock on the Nasdaq Stock Market exceeds $5.29 for five consecutive
trading days and (iv) the Company will be free to waive the terms and conditions
of any lock-up agreement between the Company and any of the former shareholders
of Jay Pharma Inc. without the consent of, or notice to, Alpha once the
registration statement registering the Series B Warrant Shares is declared
effective by the SEC.
The Purchase Agreement and the Registration Rights Agreement contain customary
representations, warranties and covenants by the Company, customary conditions
to closing, indemnification obligations of the Company and the Purchasers, other
obligations of the parties and termination provisions. The representations,
warranties and covenants contained in the Purchase Agreement and the
Registration Rights Agreement were made only for purposes of such agreements and
as of specific dates, were solely for the benefit of the parties to such
agreements, and may be subject to limitations agreed upon by the contracting
parties.
The net proceeds to the Company from the Offering, after deducting fees and
expenses and the Company's estimated offering expenses, and excluding the
proceeds, if any, from the exercise of the Pre-funded Warrants and Warrants, are
expected to be approximately $9,000,000. The Company currently intends to use
these net proceeds for working capital purposes.
The description of the terms and conditions of the Purchase Agreement, the
Pre-funded Warrants, the Warrants, the Registration Rights Agreement, and the
Letter Agreement set forth herein do not purport to be complete and are
qualified in their entirety by the full text of the Purchase Agreement, the
Pre-funded Warrants, the Warrants, the Registration Rights Agreement, and the
Letter Agreement, copies of which are filed as Exhibits 10.1, 4.1, 4.2, 10.2,
and 10.3, respectively, to this Current Report on Form 8-K and are incorporated
herein by reference.
Item 3.02 Unregistered Sales of Equity Securities.
The information contained in Item 1.01 of this Current Report on Form 8-K in
relation to the Warrants and Warrant Shares is incorporated herein by reference.
Item 8.01 Other Events.
On January 12, 2021, the Company issued a press release regarding the
transaction described above under Item 1.01 of this Current Report on Form 8-K.
A copy of the press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No. Description
4.1 Form of Pre-funded Warrant
4.2 Form of Warrant
10.1 Form of Securities Purchase Agreement
10.2 Form of Registration Rights Agreement
10.3 Letter Agreement, dated January 11, 2021
99.1 Press Release, dated January 12, 2021
© Edgar Online, source Glimpses